Stock Watch

Ranbaxy Laboratories has settled its patent clash with GlaxoSmithKline (GSK) over the migraine drug, Imitrex. According to the settlement, Ranbaxy will be capable of distributing generic version of the drugs in three different potencies (25 mg, 50 mg and 100 mg) in the United States from December, 2008. Ranbaxy claims that Imitrex’s annual market sales stood at $985 million. However, other details of the settlement agreement were not disclosed. During the six-month period, the drug could bring the company $90-100 million in sales the company analyst said. Dr. Reddy, which has an agreement with GSK to sell authorised generic drug version will also be selling sumatriptan succinate tablets, or generic Imitrex during the period. This is the third out of court settlement for Ranbaxy for billion dollar drugs in the last six month. In July, 2007 last year, the company declared a contract with GlaxoSmithKline for Valtrex that it anticipates to launch with 180-day market exclusivity during the second half of 2009.